GPC3-targeted IL-15 armored CAR-T cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GPC3-targeted IL-15 armored CAR-T cells, covering 2026-01-21 to 2026-01-21. Get the full timeline:
Most recent: Clinical Trial Update: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors [Phase 1]